drugset / Trial / NCT05423106

A Single and Multiple Ascending Dose Study of JNJ-64457744

NCT05423106

Phase 1 Terminated 60 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of: single ascending dose (SAD) and multiple ascending dose (MAD) administration of JNJ-64457744, administered to healthy adult participants (Part 1 and Part 3), including a cohort of Asian participants (Part 1); and after single dose administration of JNJ-64457744 to chronic hepatitis B (CHB) participants who are virologically suppressed on nucleos(t)ide analog (NA) treatment (tenofovir disoproxil fumarate \[TDF\], tenofovir alafenamide \[TAF\], or entecavir \[ETV\]) (Part 2).

Timeline

Start
2022-07-04
Primary completion
2023-03-14
Completion
2023-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64457744 Unknown Oral
Background Entecavir Small molecule Oral
Background Tenofovir disoproxil fumarate Small molecule Oral
Background tenofovir alafenamide Small molecule Oral